ebola
viru
outbreak
makona
epidem
west
africa
episod
deadli
filoviru
antivir
current
clinic
avail
find
suggest
interferon
gamma
fdaapprov
drug
may
serv
novel
effect
prophylact
treatment
option
use
mouseadapt
ebola
viru
found
murin
interferon
gamma
administ
hour
infect
robustli
protect
lethallychalleng
mice
reduc
morbid
serum
viral
titer
furthermor
demonstr
interferon
gamma
profoundli
inhibit
ebola
viru
infect
macrophag
earli
cellular
target
infect
earli
six
hour
follow
vitro
infect
ebola
viru
rna
level
interferon
gammatr
macrophag
lower
infect
untreat
cell
addit
protein
synthesi
inhibitor
cycloheximid
interferon
gammatr
macrophag
reduc
viral
rna
level
suggest
interferon
gamma
block
life
cycl
event
requir
protein
synthesi
viru
replic
microarray
studi
interferon
gammatr
human
macrophag
identifi
interferonstimul
gene
ectop
express
select
group
gene
inhibit
ebola
viru
infect
studi
provid
new
potenti
avenu
antivir
target
gene
previous
appreci
inhibit
neg
strand
rna
virus
specif
ebola
viru
infect
treatment
interferon
gamma
robustli
protect
mice
lethal
ebola
viru
infect
propos
interferon
gamma
evalu
efficaci
prophylact
andor
therapeut
strategi
filovirus
use
fdaapprov
drug
could
rapidli
deploy
futur
outbreak
filoviru
outbreak
occur
sporad
increas
frequenc
current
approv
filoviru
therapeut
makona
ebola
viru
epidem
guinea
sierra
plo
pathogen
ebola
viru
ebov
member
genu
ebolaviru
within
filovirida
famili
highli
pathogen
virus
virus
caus
sever
hemorrhag
fever
syndrom
human
nonhuman
primat
nhp
ebov
infect
frequent
associ
high
mortal
rate
respons
devast
west
african
ebov
outbreak
outbreak
gener
renew
emphasi
develop
approv
safe
effect
prophylact
therapeut
viru
macrophag
dendrit
cell
dc
play
import
role
ebov
pathogenesi
site
earli
sustain
viru
replic
ebov
infect
caus
dysregul
antigenpres
cell
increas
product
releas
proinflammatori
protein
vasoact
molecul
coagul
factor
proinflammatori
molecul
recruit
target
cell
site
infect
provid
addit
cell
viru
infect
increas
circul
inflammatori
cell
protein
uncontrol
amplif
infect
cytokin
product
result
dysregul
inflammatori
respons
lead
system
spread
viru
excess
cytokin
accumul
circulatori
collaps
observ
case
fatal
ebov
hemorrhag
fever
human
nonhuman
primat
contribut
amplifi
dysregul
ebov
sustain
replic
macrophag
dc
counteract
earli
innat
immun
respons
therebi
decreas
effect
host
respons
viru
event
combin
decreas
cell
number
observ
ebovinfect
individu
thought
lead
poor
adapt
immun
respons
infect
disrupt
ebov
infect
macrophag
would
predict
decreas
viru
load
associ
virusinduc
cytokin
dysfunct
one
approach
control
viru
replic
macrophag
elicit
earli
innat
immun
respons
respons
could
trigger
prior
virusmedi
inhibit
respons
system
control
ebov
replic
possibl
previou
studi
investig
abil
type
interferon
ifn
decreas
ebov
morbid
mortal
mix
result
jahrl
et
al
demonstr
administr
significantli
alter
cours
ebov
cynomolgu
macaqu
recent
shown
prolong
surviv
rhesu
macaqu
addit
combin
type
ifn
three
monoclon
antibodi
mab
ebov
glycoprotein
gp
provid
robust
protect
lethal
challeng
neither
ifn
mab
alon
highli
efficaci
abil
ifn
type
ifn
control
ebov
infect
explor
sever
line
reason
suggest
type
ii
ifn
interferon
gamma
would
inhibit
ebov
infect
macrophag
macrophag
treat
alon
combin
tumor
necrosi
factor
alpha
activ
toward
phenotyp
characterist
proinflammatori
antivir
enhanc
host
defens
directli
stimul
express
number
interferonstimul
gene
isg
antivir
activ
treatment
would
predict
gener
macrophag
resist
ebov
infect
sinc
thought
ebov
infect
macrophag
respons
dysregul
cytokin
product
reduc
infect
would
like
reduc
aberr
cytokin
product
concomitantli
final
potent
activ
cell
respons
enhanc
phagocytosi
antigen
present
stimul
antigen
present
would
predict
enhanc
adapt
immun
respons
vivo
infect
demonstr
block
ebov
infect
murin
periton
macrophag
robustli
protect
mice
fatal
ebov
infect
administ
late
hour
follow
infect
also
identifi
novel
gene
inhibit
ebov
infect
defin
new
downstream
mechan
fdaapprov
drug
function
studi
evalu
inhibit
model
viru
ebov
recombin
vesicular
stomat
viru
vsv
encod
ebov
glycoprotein
ebov
gprvsv
interferon
receptor
knock
ifnar
mice
highli
effect
inhibit
infect
recombin
viru
compar
use
recombin
viru
parallel
ebov
wildtyp
vsv
permit
us
evalu
mechan
inhibit
greater
detail
latter
find
suggest
may
efficaci
ebov
also
broader
rang
mononegaviral
mous
periton
macrophag
treat
hour
either
granulocytemacrophag
coloni
stimul
factor
gmcsf
macrophag
coloni
stimul
factor
mcsf
support
robust
infect
recombin
ebov
formerli
zair
ebov
express
green
fluoresc
protein
gfp
fig
mcsftreat
cell
consist
permiss
ebov
infect
gmcsftreat
cell
consequ
mcsftreat
macrophag
primarili
investig
studi
observ
mcsftreat
periton
macrophag
cultur
also
pretreat
combin
highli
resist
ebov
infect
fig
addit
cytokin
macrophag
shown
gener
proinflammatori
phenotyp
evid
combin
cytokin
alon
elicit
phenotyp
isol
macrophag
includ
signific
increas
express
proinflammatori
gene
cell
presenc
absenc
ebov
infect
fig
sinc
experi
contain
hazard
difficult
expens
model
viru
recombin
infecti
vesicular
stomat
viru
rvsv
express
ebov
gp
ebov
gprvsv
frequent
use
studi
number
aspect
filoviru
biolog
infect
periton
macrophag
ebov
gprvsv
result
remark
similar
effect
gmcsf
mcsf
combin
treatment
observ
ebov
compar
fig
fig
thu
throughout
investig
mani
studi
initi
perform
ebov
gprvsv
subsequ
confirm
extend
ebov
set
use
ebov
gprvsv
next
sought
assess
rel
contribut
inhibit
viru
infect
treatment
mcsftreat
periton
macrophag
inhibit
ebov
gprvsv
replic
addit
prevent
infect
either
balbc
periton
macrophag
fig
thu
subsequ
studi
sole
focus
impact
infect
confirm
import
inhibit
ebov
infect
increas
concentr
evalu
viru
inhibit
murin
reduc
ebov
infect
dosedepend
manner
pgml
inhibit
infect
ngml
provid
greater
protect
fig
abil
inhibit
viru
infect
also
demonstr
human
macrophag
studi
sixday
mcsf
matur
human
monocyt
deriv
macrophag
hmdm
treat
hour
prior
infect
andor
similar
murin
macrophag
find
mcsfmatur
hmdm
highli
permiss
ebov
gprvsv
infect
human
effect
profoundli
block
number
cell
infect
recombin
viru
fig
dosedepend
manner
pgml
reduc
ebov
gprvsv
replic
ngml
reduc
titer
assess
end
point
dilut
four
order
magnitud
fig
addit
determin
human
inhibit
ebov
gprvsv
infect
vivo
matur
macrophag
popul
human
alveolar
macrophag
cell
isol
bronchial
lavag
phenotyp
previous
describ
similar
mdm
cultur
mcsftreat
cell
permiss
viru
wherea
addit
prevent
infect
cell
fig
inhibit
requir
signal
type
ii
interferon
receptor
mous
macrophag
signal
type
ii
ifn
receptor
therebi
activ
jakstat
pathway
initi
express
mani
isg
howev
low
concentr
type
ifn
enhanc
respons
type
ii
ifn
high
concentr
inhibit
assess
antivir
effect
macrophag
independ
type
ifn
receptor
signal
periton
macrophag
harvest
interferon
receptor
knockout
mice
ifnar
cultur
hour
mcsf
mcsf
plu
prior
ebov
gprvsv
infect
treatment
balbc
ifnar
macrophag
inhibit
viru
infect
fig
indic
requir
presenc
function
type
ifn
receptor
antivir
effect
verifi
respons
requir
type
ii
receptor
receptor
knockout
periton
macrophag
harvest
stimul
mcsf
mcsf
plu
prior
infect
expect
treatment
effect
ebov
gprvsv
viral
titer
cell
indic
type
ii
ifn
receptor
requir
inhibit
viru
infect
fig
studi
indic
block
ebov
ebov
gprvsv
infect
macrophag
wildtyp
mice
ebov
gprvsv
infect
cell
modest
viru
spread
cultur
observ
contrast
macrophag
balbc
ifnar
mice
highli
permiss
ebov
gprvsv
treatment
cell
profoundli
decreas
infect
dose
depend
manner
fig
henc
use
periton
macrophag
ifnar
mice
subsequ
studi
ebov
gprvsv
identifi
step
viru
life
cycl
isar
block
balbc
ifnar
periton
macrophag
treat
hour
infect
ebov
gprvsv
monitor
viral
rna
accumul
via
qrtpcr
hour
infect
treatment
signific
effect
quantiti
vsv
matrix
polymeras
l
rna
detect
suggest
affect
earli
event
life
cycl
entri
fig
previou
studi
support
observ
treatment
differenti
hmdm
significantli
reduc
entri
ebov
virallik
particl
vlp
howev
hour
infect
steadi
increas
vsv
l
rna
level
infect
mcsfstimul
periton
macrophag
significantli
reduc
treatment
fig
gene
express
mononegaviral
virus
includ
filovirus
rhabdovirus
initi
primari
transcript
mrna
requir
new
viral
protein
synthesi
howev
subsequ
viral
genom
replic
requir
viral
protein
product
replic
genom
block
inhibitor
protein
synthesi
cycloheximid
chx
therefor
narrow
step
within
life
cycl
affect
compar
abil
chx
inhibit
viral
rna
product
determin
combin
two
drug
inhibit
viral
rna
level
greater
extent
balbc
ifnar
periton
macrophag
treat
mcsf
presenc
absenc
hour
initi
ebov
infect
condit
chx
ad
viral
rna
level
assess
hour
infect
chx
suppress
ebov
nucleoprotein
np
polymeras
l
rna
level
equal
combin
inhibitor
reduc
ebov
rna
product
fig
similar
result
observ
ebov
gprvsv
infect
harvest
hour
fig
total
find
indic
treatment
interfer
rna
synthesi
depend
upon
protein
synthesi
suggest
viru
replic
block
type
type
ii
ifn
treatment
macrophag
elicit
express
hundr
ifn
stimul
gene
isg
suppress
express
addit
smaller
group
gene
product
isg
protein
alter
macrophag
function
protect
cell
viral
infect
gene
set
activ
two
type
ifn
overlap
type
ii
ifn
also
stimul
uniqu
subset
gene
determin
impact
stimul
gene
express
macrophag
cultur
perform
microarray
analys
identifi
gene
least
twofold
increas
decreas
express
sixday
tabl
parallel
gene
array
perform
alveolar
macrophag
gene
identifi
alter
express
fig
tabl
fortyon
significantli
alter
gene
identifi
array
fig
fig
pathway
analysi
gene
profil
discov
top
gene
array
involv
immun
respons
develop
signal
transduct
atp
metabol
transcript
fig
array
identifi
express
isg
known
primaryrespons
gene
transcript
factor
poorli
studi
secondaryrespons
isg
gbp
apolipoprotein
l
famili
protein
thought
regul
irf
consist
previou
report
number
chemokin
inhibit
ebola
viru
infect
complement
compon
also
highli
upregul
array
find
valid
examin
mrna
level
sever
top
isg
includ
qrtpcr
fig
fig
hela
cell
infect
ebov
hour
follow
electropor
isgrfp
lentivir
construct
infect
assess
microscopi
hour
later
percent
cell
gfp
posit
calcul
cellprofil
imag
analysi
softwar
lentivir
construct
express
serv
posit
control
studi
knock
increas
ebov
gprvsv
infect
follow
stimul
scrambl
scr
sirna
load
hek
deriv
exosom
sirna
load
exosom
deliv
ad
balbc
ifnar
periton
macrophag
hour
prior
ebov
gprvsv
infect
moi
twentyfour
hour
follow
infect
total
rna
isol
macrophag
amount
express
infect
detect
vsv
polymeras
l
quantifi
qrtpcr
result
repres
mean
sem
signific
determin
student
ttest
analysi
p
p
p
assess
import
significantli
upregul
isg
control
ebov
gprvsv
ebov
infect
gene
transfect
cell
effect
viru
infect
assess
panel
isg
includ
wellstudi
poorli
character
gene
eight
lentivir
construct
express
isg
red
fluoresc
protein
rfp
assess
inhibit
ebov
gprvsv
ebov
highli
permiss
cell
transfect
construct
express
strongli
inhibit
ebov
gprvsv
ebov
replic
previous
shown
posit
strand
neg
strand
rna
virus
fig
transcript
factor
critic
signal
drive
downstream
express
mani
target
gene
also
assess
knock
mcsftreat
macrophag
alter
infect
ebov
gprvsv
periton
macrophag
sirna
scrambl
control
sirna
deliv
periton
macrophag
exosom
sinc
direct
sirna
transfect
macrophag
highli
ineffici
valid
sirna
deliveri
method
initi
demonstr
exosom
effici
engulf
murin
periton
macrophag
fig
context
ebov
gprvsv
infect
deliveri
sirna
contain
exosom
knock
mrna
level
approxim
mcsfand
macrophag
fig
knock
signific
increas
ebov
gp
rvsv
rna
observ
hour
follow
infect
consist
import
express
control
viru
infect
addit
less
wellcharacter
isg
highli
upregul
gene
array
studi
also
assess
abil
directli
control
viru
infect
ectop
express
result
signific
inhibit
ebov
gprvsv
fig
evalu
isg
abil
inhibit
ebov
demonstr
also
effect
block
ebov
identifi
novel
isg
like
import
control
ebov
cell
surprisingli
express
modestli
inhibit
ebov
gprvsv
infect
like
signific
level
constitut
express
within
cell
control
activ
primarili
regul
phosphoryl
statu
certainli
isg
test
highli
upregul
gene
array
inhibit
viru
replic
effect
ebov
gprvsv
vivo
treatment
protect
ifnar
mice
lethal
ebov
gp
rvsv
challeng
less
efficaci
wildtyp
vsv
sinc
robustli
inhibit
ebov
gprvsv
ebov
infect
macrophag
macrophag
import
cellular
target
filovirus
pathogenesi
evalu
abil
intraperiton
ip
administ
protect
mice
lethal
ip
challeng
studi
balbc
ifnar
mice
use
littl
pathogenesi
observ
ebov
gprvsv
infect
wildtyp
mice
signific
morbid
mortal
occur
ifnar
mice
initi
dose
respons
studi
demonstr
protect
ifnar
mice
lethal
ebov
gprvsv
challeng
fig
neither
dose
detect
consequ
weight
health
mice
therefor
subsequ
studi
perform
dosag
administ
ip
inject
hour
prior
hour
lethal
dose
ebov
gprvsv
protect
mice
challeng
treat
mice
demonstr
significantli
reduc
mortal
weight
loss
clinic
sick
score
compar
untreat
virusinfect
anim
fig
dose
also
assess
surviv
mice
given
hour
challeng
mice
surviv
challeng
post
challeng
group
protect
offer
treatment
statist
differ
confer
time
point
proxim
challeng
fig
howev
administ
hour
follow
ebov
gprvsv
protect
mice
lethal
challeng
consist
reduc
morbid
mortal
ebov
gprvsv
infect
mice
mice
treat
hour
infect
dramat
lower
ebov
gprvsv
viremia
day
infect
fig
littl
detect
viral
load
observ
liver
periton
lymph
node
brain
pretreat
mice
somewhat
higher
level
viru
present
spleen
similar
trend
observ
mice
treat
hour
follow
ebov
gprvsv
infect
fig
splenic
viru
load
higher
mice
suggest
viru
traffick
spleen
hour
follow
inocul
nonetheless
treatment
still
control
viru
titer
organ
assess
impact
treatment
cell
site
infect
periton
cell
isol
hour
follow
ebov
gprvsv
infect
untreat
mice
treat
periton
cell
reduc
viral
rna
level
compar
infect
pbstreat
control
cell
regardless
whether
given
hour
prior
hour
follow
challeng
find
suggest
activ
infect
site
challeng
ongo
hour
follow
infect
administr
either
earli
time
point
follow
infect
abl
profoundli
reduc
viru
load
site
viru
challeng
fig
control
studi
also
evalu
abil
protect
wildtyp
vsv
infect
initi
studi
demonstr
equival
concentr
vsv
virul
mice
recombin
viru
ebov
gprvsv
perhap
broad
cellular
tropism
confer
nativ
vsv
glycoprotein
g
consequ
studi
use
infecti
unit
vsv
challeng
viru
lowest
concentr
vsv
result
predict
death
ifnar
mice
challeng
vsv
given
either
hour
prior
hour
challeng
pretreat
mice
signific
protect
mortal
still
observ
surprisingli
surviv
posttreat
mice
significantli
differ
pbstreat
vsv
infect
mice
fig
find
stand
contrast
robust
protect
confer
hour
follow
ebov
gprvsv
challeng
find
suggest
vsv
infect
less
sensit
particularli
administ
postchalleng
antivir
previou
studi
demonstr
treatment
administ
intramuscular
im
inject
allow
slower
releas
extend
halflif
drug
inject
rout
util
mani
clinic
therapeut
thu
investig
abil
administr
rout
protect
mice
lethal
ebov
gprvsv
mice
given
im
inject
hour
prior
ebov
gprvsv
infect
significantli
protect
lethal
challeng
fig
base
promis
result
observ
protect
ebov
gprvsv
infect
mice
next
sought
determin
abil
protect
mice
lethal
challeng
mouseadapt
ebov
maebov
balbc
mice
administ
ip
challeng
ip
maebov
hour
later
initi
dose
respons
studi
indic
mice
pretreat
better
protect
maebov
treatment
fig
thu
subsequ
studi
mice
challeng
maebov
administ
sinc
given
hour
follow
infect
protect
ifnar
mice
ebov
gprvsv
fig
studi
assess
protect
confer
maebov
administ
hour
prior
time
infect
hour
follow
infect
mice
regardless
time
treatment
significantli
less
morbid
mortal
untreat
infect
mice
treatment
late
hour
follow
infect
protect
mice
death
fig
lower
maebov
viremia
level
observ
hour
post
challeng
treat
mice
hour
preinfect
treatment
group
suggest
administr
postexposur
antivir
may
prove
efficaci
use
prophylact
fig
result
first
demonstr
abil
protect
anim
prophylact
therapeut
ebov
infect
suggest
fdaapprov
drug
may
use
antivir
individu
recent
highrisk
exposur
treatment
profoundli
inhibit
ebov
infect
periton
macrophag
tissu
cultur
consist
protect
confer
evid
cell
type
import
earli
target
viru
replic
sinc
antivir
efficaci
requir
presenc
receptor
type
receptor
control
ebov
infect
occur
independ
type
ifn
respons
thu
sought
identifi
specif
gene
involv
antivir
effect
addit
previous
character
isg
identifi
three
novel
factor
date
shown
control
neg
strand
rna
viru
infect
final
demonstr
recombin
viru
ebov
gprvsv
recapitul
find
ebov
argu
studi
model
viru
may
serv
safer
cost
effect
altern
initi
evalu
novel
antifilovir
agent
antivir
activ
confer
member
mononegaviral
previous
report
instanc
addit
pteropu
alecto
bat
cell
protect
paramyxovirus
semiki
forest
viru
hendra
viru
addit
sever
line
evid
indic
effect
rabi
viru
tissu
cultur
vivo
potenti
stimul
type
ifn
pathway
studi
also
suggest
treatment
specif
target
ebov
protect
recombin
viru
ebov
gprvsv
modest
degre
vsv
mice
lack
type
ifn
signal
howev
time
protect
wildtyp
ebov
wildtyp
vsv
differ
treatment
protect
vsv
given
prior
infect
wherea
postchalleng
treatment
appear
somewhat
efficaci
ebov
prechalleng
treatment
recent
studi
demonstr
isg
sole
synthes
first
hour
follow
ifn
stimul
wherea
other
express
longer
period
time
differ
time
protect
vsv
versu
ebov
suggest
isg
respons
protect
may
differ
futur
studi
need
explor
possibl
sinc
mice
challeng
ebov
gprvsv
protect
treatment
post
challeng
time
point
manner
similar
ebov
differ
time
protect
may
relat
cell
popul
target
two
wildtyp
virus
studi
begun
identifi
protein
contribut
control
ebov
infect
studi
type
ifn
shown
subset
isg
preferenti
target
neg
strand
rna
virus
may
case
isg
well
surprisingli
express
transcript
factor
inhibit
ebov
infect
isg
serv
posit
control
experi
downstream
isg
select
studi
base
enhanc
express
elicit
gene
array
studi
avail
express
construct
abil
inhibit
neg
strand
rna
virus
poorli
studi
mechan
drive
inhibit
viru
replic
remain
elucid
isg
reduc
ebov
infect
howev
shown
virus
combin
isg
like
provid
addit
even
synergist
inhibit
isg
target
independ
modulatori
pathway
also
demonstr
knockdown
could
modestli
rescu
ebov
gprvsv
infect
periton
macrophag
stimul
contain
predict
bind
site
base
analysi
genom
sequenc
ucsf
genom
browser
addit
recent
studi
demonstr
murin
bonemarrow
deriv
macrophag
significantli
decreas
gene
express
compar
wt
cell
follow
francisella
novicida
infect
togeth
observ
suggest
transcript
stimul
may
control
express
novel
isg
turn
particip
control
ebov
infect
identif
isg
inhibit
ebov
infect
add
isg
identifi
target
viru
date
limit
number
isg
identifi
restrict
ebov
infect
includ
tetherin
rigi
addit
identifi
inhibit
ebov
entri
isg
block
ebov
gpdepend
entri
interestingli
studi
express
significantli
upregul
macrophag
consist
see
impact
total
viral
rna
present
cell
earli
time
infect
hour
suggest
earli
event
affect
treatment
consist
previou
studi
demonstr
affect
ebov
gpdepend
entri
reduc
viral
rna
level
manner
similar
observ
protein
synthesi
inhibitor
cycloheximid
suggest
inhibit
one
viral
life
cycl
event
downstream
translat
isg
previous
identifi
block
viral
protein
translat
includ
oligoadenyl
synthetas
indoleamin
howev
date
none
assess
abil
inhibit
ebov
replic
express
isg
significantli
increas
macrophag
like
contribut
inhibit
ebov
infect
observ
produc
sever
differ
hematopoiet
cell
type
includ
natur
killer
cell
natur
killer
cell
lymphocyt
induc
specif
cytotox
antivir
immun
direct
isg
product
indirect
mechan
like
provid
addit
mechan
action
benefit
clinic
profil
ad
effect
includ
assist
activ
adapt
immun
system
interact
lead
upregul
phagocytosi
antigen
process
present
dc
macrophag
drive
product
phenotyp
cell
rel
import
divers
array
downstream
effect
ebov
infect
still
need
elucid
ebov
evad
host
innat
immun
signal
pathway
impair
type
type
ii
ifn
signal
dysregul
proinflammatori
cytokin
express
suppress
dc
matur
tcell
activ
immun
dysregul
thought
allow
ebov
gain
upper
hand
cours
infect
howev
reduct
viral
antigen
littl
appear
differ
host
surviv
death
ebov
infect
treatment
ebov
infect
mice
late
hour
follow
lethal
challeng
demonstr
effect
control
viral
load
treatment
like
assist
overcom
ebovinduc
impair
immun
function
activ
matur
immun
cell
well
elicit
isg
lead
reduc
ebov
rna
product
well
perhap
innat
immun
control
aspect
ebov
life
cycl
filoviru
pathogenesi
investig
use
varieti
differ
anim
model
includ
mice
guinea
pig
hamster
nonhuman
primat
nhp
variou
model
organ
offer
differ
advantag
studi
ebov
pathogenesi
assess
novel
antivir
treatment
nhp
consid
repres
model
ebov
infect
display
similar
symptom
observ
human
expens
ethic
use
anim
limit
late
phase
preclin
studi
contrast
infect
mice
maebov
serv
good
genet
manipulat
small
anim
model
earli
phase
evalu
vaccin
therapeut
intervent
allow
assess
impact
viral
pathogenesi
definit
evid
efficaci
small
anim
model
pave
way
futur
nhp
studi
assay
antiebov
properti
vivo
studi
suggest
may
serv
effect
prophylact
andor
therapeut
drug
ebov
infect
sever
differ
ifn
current
fda
approv
treat
varieti
infect
autoimmun
disord
type
ifn
use
clinic
therapeut
hepat
b
c
infect
show
mix
efficaci
ebov
infect
nhp
antivir
effect
less
wellstudi
protein
fdaapprov
therapi
chronic
granulomat
diseas
osteopetrosi
chronic
granulomat
patient
receiv
three
time
weekli
prevent
infect
serv
lifelong
protect
treatment
patient
establish
safeti
effect
disord
abil
profoundli
inhibit
ebov
infect
studi
suggest
may
serv
ebov
antivir
therapi
univers
iowa
institut
anim
care
use
committe
iacuc
guidelin
follow
anim
experi
breed
took
place
univers
iowa
guidelin
strict
adher
public
health
servic
polici
human
care
use
laboratori
anim
univers
iowa
olaw
assur
number
anim
studi
perform
univers
iowa
studi
approv
univers
iowa
iacuc
protocol
texa
biomed
research
institut
tbri
institut
anim
care
use
committe
iacuc
guidelin
follow
anim
experi
took
place
tbri
guidelin
strict
adher
public
health
servic
polici
human
care
use
laboratori
anim
tbri
olaw
assur
number
anim
studi
perform
tbri
studi
approv
tbri
iacuc
protocol
mice
balbc
mice
obtain
nation
cancer
institut
frederick
md
balbc
receptordefici
ifnar
mice
kind
gift
dr
joan
durbin
nyu
langon
medic
center
wildtyp
receptordefici
mice
kind
gift
dr
john
harti
univers
iowa
mice
bred
univers
iowa
infecti
ebov
mous
studi
perform
biosafeti
level
laboratori
tbri
studi
femal
balbc
mice
obtain
jackson
laboratori
bar
harbor
hous
specif
pathogenfre
condit
recombin
wildtyp
ebov
express
gfp
vitro
macrophag
studi
gener
previous
describ
mous
adapt
ebov
maebov
gener
vivo
mous
infect
previous
describ
product
recombin
replicationcompet
vesicular
stomat
viru
express
egfp
ebov
gp
place
g
glycoprotein
ebov
gprvsv
perform
previous
describ
ebov
gp
use
studi
gp
lack
mucin
domain
confer
tropism
fulllength
ebov
gp
produc
higher
titer
ebov
gprvsv
stock
produc
infect
vero
cell
low
multipl
infect
collect
supernat
hour
follow
infect
viruscontain
supernat
filter
filter
store
ebov
gprvsv
mous
studi
concentr
centrifug
x
g
overnight
viru
pellet
resuspend
centrifug
sucros
cushion
ultracentrifug
rpm
hour
pellet
resuspend
pb
aliquot
frozen
use
gener
infecti
vsv
express
egfp
util
vivo
studi
previou
describ
vsv
stock
produc
vero
cell
concentr
purifi
describ
isol
murin
periton
cell
mice
sacrif
cell
harvest
lavag
use
ml
icecold
rpmi
medium
contain
fb
recov
periton
cell
wash
cold
media
plate
presenc
ngml
murin
mcsf
biolegend
nonadher
cell
remov
hour
isol
wash
twice
pb
adher
cell
previous
character
express
macrophag
surfac
marker
hour
prior
infect
media
replac
fresh
media
contain
ngml
murin
mcsf
gmcsf
without
ngml
murin
cell
scienc
andor
murin
biolegend
unless
otherwis
indic
figur
legend
ngml
use
studi
univers
iowa
institut
review
board
irb
approv
procedur
blood
draw
obtain
inform
consent
individu
studi
involv
human
perform
approv
univers
iowa
irb
protocol
dr
monick
peripher
blood
mononuclear
cell
pbmc
isol
human
blood
use
ficollhypaqu
sigmaaldrich
monocytederiv
macrophag
mdm
isol
adher
previous
describ
isol
mdm
plate
dulbecco
modifi
eagl
medium
dmem
gibco
media
contain
fetal
bovin
serum
fb
atlanta
biolog
type
ab
human
serum
sigma
penicillinstreptomycin
ps
life
technolog
ngml
human
mcsf
r
system
mdm
differenti
day
day
media
mdm
cultur
replac
media
contain
human
mcsf
alon
without
addit
ngml
andor
r
system
unless
otherwis
indic
figur
legend
human
alveolar
macrophag
isol
bronchoalveolar
lavag
healthi
consent
human
volunt
previous
describ
follow
isol
wrightgiemsastain
cytocentrifug
protocol
util
differenti
count
total
number
alveolar
macrophag
prepar
cell
prepar
alveolar
macrophag
alveolar
macrophag
cultur
rpmi
media
contain
human
serum
fb
ps
ngml
human
mcsf
r
system
stimul
ngml
human
hour
prior
infect
ebov
balbc
periton
macrophag
isol
lavag
describ
plate
presenc
ngml
murin
gmcsf
mcsf
prophylact
treatment
cell
treat
ngml
murin
andor
murin
hour
prior
infect
cell
refresh
media
without
addit
cytokin
transfer
facil
tbri
hour
cell
isol
challeng
replicationcompet
ebov
encod
gfp
moi
cell
analyz
hour
follow
infect
describ
previous
briefli
cell
fix
stain
hoescht
dye
imag
nikon
tieclips
microscop
use
highcontentanalysi
softwar
packag
nikon
tokyo
japan
imag
process
nuclei
identifi
hoescht
dye
fluoresc
total
cell
cell
express
gfp
count
use
cell
profil
softwar
broad
institut
mit
boston
massachusett
use
custom
pipelin
avail
r
davey
upon
request
data
express
percent
gfp
posit
cell
ebov
gprvsv
cytokinecontain
media
remov
macrophag
replac
rpmi
fc
end
point
dilut
assay
human
murin
macrophag
popul
infect
serial
dilut
ebov
gprvsv
least
replic
per
dilut
infect
score
hour
follow
infect
gfp
posit
use
fluoresc
microscop
viru
titer
calcul
tissu
cultur
infect
dose
ml
reedmeunch
method
flow
cytometr
analysi
murin
ifnar
periton
macrophag
infect
infect
moi
base
titer
viru
stock
vero
cell
infect
quantifi
detect
gfp
posit
use
fac
calibur
flow
cytomet
bd
bioscienc
data
analyz
use
flowjo
analysi
softwar
rel
infect
quantifi
compar
mcsf
stimul
periton
macrophag
equal
alveolar
macrophag
infect
ebov
gprvsv
moi
hour
follow
isol
hour
stimul
cell
fix
paraformaldehyd
hour
follow
ebov
gprvsv
infect
cover
coverslip
use
vectashield
mount
medium
dapi
vector
laboratori
burlingam
ca
imag
alveolar
macrophag
acquir
use
leica
truepointscan
spectral
system
tc
spe
confoc
microscop
leica
applic
suit
la
af
interfac
leica
microsystem
wetzler
germani
murin
macrophag
cultur
isol
maintain
describ
cell
infect
ebov
gprvsv
maebov
moi
indic
cell
incub
minut
prior
infect
protein
synthesi
inhibitor
cycloheximid
chx
sigma
concentr
total
rna
isol
use
mirvana
mirna
isol
kit
ambionlif
technolog
hour
follow
infect
rna
quantifi
nanodrop
thermo
scientif
total
rna
ng
reversetranscrib
cdna
use
random
primer
mmlv
revers
transcriptas
invitrogen
use
manufactur
specif
quantit
revers
transcriptas
polymeras
chain
reaction
qrtpcr
use
detect
transcript
level
sybr
green
base
quantit
pcr
reaction
appli
bioscienc
perform
use
specif
primer
vsv
l
ebov
np
l
proinflammatori
cytokinechemokin
isg
ul
cdna
reaction
primer
sequenc
avail
upon
request
express
level
defin
ratio
threshold
cycl
ct
valu
housekeep
gene
hprt
determin
ratio
convert
valu
replic
experi
result
repres
fold
chang
valu
calcul
base
hour
mcsf
valu
rna
prepar
qualiti
analysi
microarray
analysi
perform
previous
describ
microarray
assess
genomewid
macrophag
mrna
express
use
genechip
human
exon
st
array
affymetrix
microarray
data
assess
pair
ttest
limma
statist
analysi
use
r
statist
softwar
http
wwwrprojectorg
data
assess
qualiti
use
normal
unscal
standard
error
nuse
analysi
method
statist
analysi
pair
ttest
array
limma
analysi
perform
compar
macrophag
array
chang
gene
express
p
valu
consid
signific
gene
pathway
analysi
conduct
use
genego
metacor
version
thompson
reuter
six
top
gene
identifi
mdm
alveolar
macrophag
microarray
analysi
valid
qrtpcr
describ
previous
describ
primer
specif
isg
use
assess
mrna
level
express
level
defin
ratio
threshold
cycl
valu
housekeep
gene
hprt
primer
sequenc
avail
upon
request
isgrfp
lentivir
construct
kind
gift
dr
charl
rice
rockerfel
univers
previous
describ
hek
cell
stabli
express
cell
routin
test
absenc
mycoplasma
transfect
isgrfp
construct
indic
concentr
fortyeight
hour
follow
transfect
cell
infect
ebovgprvsv
moi
infect
assess
use
flow
cytometri
bd
facsvers
hour
follow
infect
flow
cytometri
data
analyz
use
flowjo
cytometri
analysi
softwar
percentag
rfp
posit
cell
also
gfp
posit
rel
infect
determin
base
infect
cell
express
rfpcontrol
construct
alon
isg
inhibit
infecti
ebov
viru
perform
use
neon
invitrogen
electropor
hela
cell
ambion
austin
tx
fortyeight
hour
follow
transfect
cell
infect
ebovgfp
moi
hour
infect
quantifi
describ
previous
briefli
imag
analyz
use
cell
profil
quantifi
rfp
gfp
posit
cell
data
analyz
fc
express
analysi
softwar
cell
gate
base
infect
control
isol
exosom
day
exosom
collect
cultur
medium
hek
cell
replac
dmem
supplement
prespun
fb
avoid
contamin
fb
deriv
exosom
fb
spun
x
g
hour
cultur
supernat
hek
cell
collect
exosom
isol
supernat
differenti
centrifug
describ
previous
brief
cell
supernat
clear
intact
cell
cell
debri
centrifug
x
g
minut
x
g
minut
supernat
subject
filtrat
amicon
filter
supernat
concentr
kda
mwco
centricon
millipor
ml
concentr
supernat
spun
x
g
minut
tla
rotor
beckman
coulter
pellet
exosom
collect
exosom
wash
twice
pb
recoveri
exosom
estim
measur
protein
concentr
use
bradford
assay
exosom
label
confoc
imag
exosom
load
cellmask
deep
red
plasma
membran
stain
minut
exosom
wash
pb
centrifug
x
g
minut
tla
rotor
beckman
coulter
pellet
exosom
resuspend
cultur
medium
imag
periton
macrophag
cell
allow
attach
eightwel
chamber
slide
ten
microgram
exosom
load
cellmask
appli
periton
macrophag
imag
hour
follow
treatment
exosom
uptak
visual
leica
tc
confoc
microscop
leica
microsystem
inc
buffalo
grove
il
cell
fix
paraformaldehyd
mount
vectashield
dapi
vector
laboratori
inc
burlingam
ca
imag
load
dsirna
exosom
dicersubstr
rna
dsirna
idt
duplex
rna
increas
potenc
rna
interfer
compar
tradit
sirna
load
exosom
electropor
describ
briefli
exosom
pellet
resuspend
electropor
buffer
sirna
load
electropor
mixtur
prepar
mix
exosom
dsirna
wtwt
electropor
buffer
final
concentr
exosom
mixtur
mixtur
electropor
volum
use
cuvett
mv
capacit
puls
time
ms
exosom
aliquot
frozen
use
exosom
knockdown
ebov
gprvsv
infect
balbc
ifnar
periton
macrophag
isol
describ
cultur
cell
format
presenc
mcsf
hour
prior
addit
dsirna
load
exosom
scrambl
scr
sirna
load
exosom
ad
macrophag
fresh
media
fresh
mcsf
without
macrophag
exosom
spinocul
centrifug
x
g
hour
incub
hour
twentyfour
hour
later
media
exosom
cytokin
remov
macrophag
infect
fresh
media
contain
ebov
gprvsv
moi
twentyfour
hour
follow
infect
cell
lyse
describ
rna
extract
rna
isol
cdna
synthesi
quantif
express
qpcr
perform
describ
express
level
defin
ratio
threshold
cycl
ct
valu
vsvl
housekeep
gene
mous
hprt
display
valu
ratio
parallel
experi
mice
administ
hour
follow
ebov
gprvsv
infect
ip
inject
vsv
studi
post
challeng
administr
given
hour
follow
infect
mice
weigh
score
sick
daili
clinic
sick
score
follow
appar
ill
slightli
ruffl
fur
ruffl
fur
activ
ruffl
fur
inact
ruffl
fur
inact
hunch
postur
moribund
dead
result
repres
score
least
mice
per
group
mous
infect
studi
conclud
day
follow
infect
due
surviv
mice
regain
lost
weight
sign
clinic
ill
maebov
infect
fiveweekold
femal
balbc
mice
administ
cell
scienc
indic
concentr
pb
ip
inject
hour
prior
time
hour
follow
viru
challeng
mice
inject
ip
plaqu
form
unit
pfu
mouseadapt
ebov
mice
observ
daili
weight
loss
clinic
score
surviv
anim
sacrif
day
ebov
gprvsv
infect
organ
harvest
day
follow
infect
least
mice
treatment
group
mice
anesthet
isofluoren
perform
retroorbit
bleed
serum
mice
euthan
perfus
ml
pb
heart
prior
harvest
organ
total
periton
cell
popul
isol
lyse
qrtpcr
detect
viral
rna
describ
organ
homogen
pb
titer
determin
endpoint
dilut
describ
mycoplasmafre
vero
cell
maebov
infect
four
day
follow
infect
three
anim
per
group
sacrif
sera
isol
blood
sampl
store
use
viru
load
quantifi
cultur
serial
dilut
serum
pb
mycoplasma
free
cell
seed
well
plate
one
hour
incub
supernat
replac
dmem
contain
methylcellulos
fb
cell
incub
day
cell
fix
formalin
overnight
stain
crystal
violet
plaqu
manual
count
statist
method
use
predetermin
sampl
size
tissu
cultur
experi
perform
least
triplic
least
three
replic
per
experi
vivo
surviv
experi
perform
least
duplic
least
mice
per
treatment
group
maebov
ebov
gprvsv
titer
studi
perform
least
three
mice
treatment
group
possibl
vitro
vivo
studi
investig
veterinari
staff
blind
group
alloc
experi
assess
outcom
mice
sampl
randomli
assign
variou
treatment
group
data
point
anim
report
result
statist
analyz
statist
analys
perform
use
graphpad
prism
softwar
graphpad
softwar
inc
result
shown
mean
standard
error
mean
sem
twotail
unpair
student
ttest
use
compar
experiment
treatment
group
control
major
studi
report
assess
varianc
studi
f
test
compar
varianc
perform
parallel
determin
varianc
similar
group
protein
translat
inhibit
studi
oneway
analysi
varianc
anova
perform
compar
control
differ
treatment
follow
tukey
post
hoc
multipl
comparison
analysi
determin
statist
signific
nonparametr
data
mannwhitney
utest
use
logrank
mantelcox
test
use
analyz
differ
surviv
p
valu
less
consid
signific
death
mice
particular
day
indic
cross
valu
indic
number
mice
succumb
infect
b
enhanc
surviv
ebov
gprvsv
infect
mice
modestli
enhanc
surviv
follow
wildtyp
vsv
infect
pb
administ
ip
inject
balbc
ifnar
mice
hour
prior
hour
follow
iu
ebov
gprvsv
iu
vsv
infect
n
protect
studi
also
perform
hour
follow
ebov
gprvsv
challeng
signific
determin
mantelcox
test
compar
ebov
gprvsv
pb
mice
p
p
compar
vsv
pb
mice
p
p
compar
ebov
gprvsv
treat
group
vsv
treat
group
p
c
treatment
mice
hour
prior
hour
follow
ebov
gprvsv
infect
prevent
weight
loss
first
day
ebov
gprvsv
vivo
infect
treatment
protect
weight
loss
earli
day
follow
infect
given
hour
prior
hour
follow
ebov
gprvsv
c
result
repres
mean
sem
bd
treatment
group
consist
least
mice
per
group
signific
determin
student
ttest
compar
pb
control
p
find
panel
ac
repres
mice
per
group
one
experi
treatment
inhibit
maebov
viremia
serum
collect
day
follow
infect
viral
load
quantifi
serial
dilut
serum
cell
determin
pfuml
data
repres
mice
per
group
signific
determin
student
ttest
compar
pb
control
p
tif
tabl
stimul
gene
significantli
alter
human
mdm
treat
ng
ml
assess
gene
array
analysi
isg
assess
studi
bold
xlsx
tabl
stimul
gene
significantli
alter
human
alveolar
macrophag
treat
ngml
assess
gene
array
analysi
isg
assess
studi
bold
xlsx
